{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:59:15Z","timestamp":1774241955683,"version":"3.50.1"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2020,5,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Bacterial conjunctivitis is a serious ocular infection if left\nuntreated. It is caused by several species of bacteria like Pseudomonas, Staphylococcus\nand Mycobacterium.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present investigation explores the development and characterization of\nmoxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL\n100 nanosuspension for ocular drug delivery in order to overcome the problems associated\nwith conventional dosage forms.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The nanosuspension prepared by nanoprecipitation technique showed successful\nentrapment of both water-soluble drugs in the polymer matrix indicated by their %\nentrapment efficiencies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Formulations showed a mean particle size &lt;200 nm with narrow size distribution\nand positive surface charge due to the presence of quaternary ammonium groups of\nEudragit RL100. FTIR study revealed compatibility among the components, while a\nreduction in the crystallinity of formulation was observed in the PXRD study. The release\nof both the drugs was found to be sustained in nanosuspension as compared to commercial\neyedrops. Ex vivo studies showed increased transcorneal permeation of drugs from\nnanosuspension, where approximately 2.5-fold and 2-fold increase in the permeation was\nobserved for moxifloxacin hydrochloride and ketorolac tromethamine, respectively. The\nformulation was stable at 4\u00b0C and room temperature.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Due to their sustained release, positive surface charge and higher transcorneal\npermeation, this will be a promising ocular drug delivery.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738508666200313140902","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T13:45:41Z","timestamp":1584107141000},"page":"133-147","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery"],"prefix":"10.2174","volume":"8","author":[{"given":"Vedanti","family":"Salvi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics (PG), Gourishankar Institute of Pharmaceutical Education &Research, Limb, Survey No.990, NH-4, Satara-4150415, MS, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-1977","authenticated-orcid":true,"given":"Pravin","family":"Pawar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Annasaheb Dange College of B Pharmacy, Ashta, Tal-Walwa, Dist. Sangli-415301, MS, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/0975-8453.75042","volume":"1","author":"Patel P.B.","year":"2010","unstructured":"Patel P.B.; Shastri D.H.; Shelat P.K.; Shukla A.K.; Ophthalmic drug delivery system: challenges and approaches. Sys Rev Pharm 2010,1,113-120","journal-title":"Sys Rev Pharm"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","volume":"39","author":"Achouri D.","year":"2013","unstructured":"Achouri D.; Alhanout K.; Piccerelle P.; Andrieu V.; Recent advances in ocular drug delivery. Drug Dev Ind Pharm 2013,39(11),1599-1617","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","volume":"7","author":"Weng Y.","year":"2017","unstructured":"Weng Y.; Liu J.; Jin S.; Guo W.; Liang X.; Hu Z.; Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B 2017,7(3),281-291","journal-title":"Acta Pharm Sin B"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.2147\/OPTH.S10162","volume":"4","author":"Hutnik C.","year":"2010","unstructured":"Hutnik C.; Mohammad-Shahi M.H.; Bacterial conjunctivitis. Clin Ophthalmol 2010,4,1451-1457","journal-title":"Clin Ophthalmol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3797\/scipharm.1204-16","volume":"81","author":"Mudgil M.","year":"2013","unstructured":"Mudgil M.; Pawar P.K.; Preparation and in vitro\/ex vivo evaluation of moxifloxacin-loaded PLGA nanosuspensions for ophthalmic applications. Sci Pharm 2013,81(2),591-606","journal-title":"Sci Pharm"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/2230-973X.143114","volume":"4","author":"Kaskoos R.A.","year":"2014","unstructured":"Kaskoos R.A.; Investigation of moxifloxacin loaded chitosan-dextran nanoparticles for topical instillation into eye: In-vitro and ex-vivo evaluation. Int J Pharm Investig 2014,4(4),164-173","journal-title":"Int J Pharm Investig"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/mp900279c","volume":"7","author":"Ibrahim H.K.","year":"2010","unstructured":"Ibrahim H.K.; El-Leithy I.S.; Makky A.A.; Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin\/prednisolone bitherapy. Mol Pharm 2010,7(2),576-585","journal-title":"Mol Pharm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2165\/00003495-200767090-00004","volume":"67","author":"Colin J.","year":"2007","unstructured":"Colin J.; The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007,67(9),1291-1308","journal-title":"Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/03639045.2015.1081236","volume":"42","author":"Fathalla Z.M.","year":"2016","unstructured":"Fathalla Z.M.; Khaled K.A.; Hussein A.K.; Alany R.G.; Vangala A.; Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles. Drug Dev Ind Pharm 2016,42(4),514-524","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/2230-973X.167684","volume":"5","author":"Prabhu P.","year":"2015","unstructured":"Prabhu P.; Dubey A.; Parth V.; Ghate V.; Investigation of hydrogel membranes containing combination of gentamicin and dexamethasone for ocular delivery. Int J Pharm Investig 2015,5(4),214-225","journal-title":"Int J Pharm Investig"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0886-3350(97)80285-4","volume":"23","author":"Rossetti L.","year":"1997","unstructured":"Rossetti L.; Bellucci R.; Cillino S.; Monreale D.; Bonomi L.; Ponte F.; Orzalesi N.; Efficacy and safety of combined diclofenac 0.1% and gentamicin 0.3% eyedrops after phacoemulsification. J Cataract Refract Surg 1997,23(5),745-749","journal-title":"J Cataract Refract Surg"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/sj.eye.6700631","volume":"18","author":"Ermis S.S.","year":"2004","unstructured":"Ermis S.S.; Aktepe O.C.; Inan U.U.; Ozturk F.; Altindis M.; Effect of topical dexamethasone and ciprofloxacin on bacterial flora of healthy conjunctiva. Eye (Lond) 2004,18(3),249-252","journal-title":"Eye (Lond)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/jps.10227","volume":"91","author":"Pignatello R.","year":"2002","unstructured":"Pignatello R.; Bucolo C.; Puglisi G.; Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 2002,91(12),2636-2641","journal-title":"J Pharm Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"Costa P.","year":"2001","unstructured":"Costa P.; Sousa Lobo J.M.; Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001,13(2),123-133","journal-title":"Eur J Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"E192","DOI":"10.1208\/pt070127","volume":"7","author":"Pignatello R.","year":"2006","unstructured":"Pignatello R.; Ricupero N.; Bucolo C.; Maugeri F.; Maltese A.; Puglisi G.; Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 2006,7(1),E192-E198","journal-title":"AAPS PharmSciTech"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2478\/v10007-012-0002-5","volume":"62","author":"Pawar P.K.","year":"2012","unstructured":"Pawar P.K.; Katara R.; Majumdar D.K.; Design and evaluation of moxifloxacin hydrochloride ocular inserts. Acta Pharm 2012,62(1),93-104","journal-title":"Acta Pharm"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/02652048.2017.1321048","volume":"34","author":"Morsi N.","year":"2017","unstructured":"Morsi N.; Ghorab D.; Refai H.; Teba H.; Nanodispersion-loaded mucoadhesive polymeric inserts for prolonged treatment of post-operative ocular inflammation. J Microencapsul 2017,34(3),280-292","journal-title":"J Microencapsul"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.colsurfb.2012.10.056","volume":"103","author":"Katara R.","year":"2013","unstructured":"Katara R.; Majumdar D.K.; Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery. Colloids Surf B Biointerfaces 2013,103,455-462","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.18433\/J3SW2T","volume":"13","author":"Mandal B.","year":"2010","unstructured":"Mandal B.; Alexander K.S.; Riga A.T.; Sulfacetamide loaded Eudragit RL100 nanosuspension with potential for ocular delivery. J Pharm Pharm Sci 2010,13(4),510-523","journal-title":"J Pharm Pharm Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0378-5173(02)00380-0","volume":"247","author":"Yoshinari T.","year":"2002","unstructured":"Yoshinari T.; Forbes R.T.; York P.; Kawashima Y.; Moisture induced polymorphic transition of mannitol and its morphological transformation. Int J Pharm 2002,247(1-2),69-77","journal-title":"Int J Pharm"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/180193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T19:15:12Z","timestamp":1592594112000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/180193\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738508666200313140902","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}